RIPOR2 and neoplasm: Generally, the high RIPOR2 expression group had a lower tumor mutation burden (TMB), higher ESTIMATEScore, and higher proportions of ICPs, and patients in this group responded better to immunotherapy with PD-1 alone or combined with CTLA4.